Table 1 Fatty acid synthesis inhibitors in clinical development.
Target | Inhibitor | Condition |
|---|---|---|
ACLY | Bempedoic acid | Hyperlipidemia (FDA, EMA approved) [124] |
ACC | Clesacostat (PF-05221304) | Non-alcoholic steatohepatitis (Phase II) [125] |
ACC | Firsocostat (GS-0976) | Non-alcoholic steatohepatitis (Phase II) [126] |
FASN | Denifanstat (TVB-2640) | Non-alcoholic steatohepatitis (Phase III) [127] Metastatic solid tumors (Phase II) [128] |
FASN | ASC40 | Glioblastoma (Phase III) [129] |
SCD1 | MTI-301 | Metastatic or Unresectable and Refractory Solid Cancers (Phase I) [79] |
